Skip to main content
. 2019 Jun 19;24(12):1593–1600. doi: 10.1634/theoncologist.2019-0133

Table 1. Eligible study characteristics and patient demographics.

image

a

Both treatment arms received oral aprepitant at 125 mg on day 1 and 80 mg on days 2–3.

b

DEX d1 arm: Palonosetron with dexamethasone administration on day 1 only.

c

DEX d1–3 arm: Palonosetron with dexamethasone administration on days 1–3.

Abbreviations: AC, anthracycline plus cyclophosphamide; DEX, dexamethasone; HEC, highly emetogenic chemotherapy; IV, intravenous; MEC, moderately emetogenic chemotherapy; NA, not available; PS, performance status; Saline, physiological saline.